Article Sidebar

PDF
Date Published: 17/02/2023
Abstract Views: 201
Views PDF: 84
DOI: https://doi.org/10.51298/vmj.v520i2.4150
Issue
Vol. 520 No. 2 (2022)
Section
Các bài báo
How to Cite
Phùng, T. C. ., & Phạm , T. M. P. (2023). LUNG DAMAGE IN PATIENTS WITH SYSTEM SCLEROSIS AT THE NATIONAL HOSPITAL OF DERMATOLOGY IN 2021. Vietnam Medical Journal, 520(2). https://doi.org/10.51298/vmj.v520i2.4150

LUNG DAMAGE IN PATIENTS WITH SYSTEM SCLEROSIS AT THE NATIONAL HOSPITAL OF DERMATOLOGY IN 2021

Thị Chuyên Phùng1,, Thị Minh Phương Phạm 2
1 Hanoi Medical university
2 National Hospital of Dermatology and Venereology

Main Article Content

Abstract

Objectives: Evaluation of lung damage and analysis of some related factors in patients with systemic scleroderma. Methods: A cross-sectional descriptive study on 81 patients diagnosed with systemic scleroderma according to ACR/EULAR 2013 criteria at the National Hospital of Dermatology from January 2020 to July 2022. Results: Interstial lung damage accounted for 80,2% total patient, pulmonary hypertension 48,1%, combined ILD and PAH  34,5%. Restrictive ventilation disorder 60,5%, FVC 77,06±18,04. There was a statistically significant difference in the Rodnan score betwween SSc with PE and without PAD (18,4 and 14,3; p=0,023). There was a statistically significant difference in the indices  of FVC (72,9% and 93,8%; p=0,02); restrictive ventilation disorder (OR=0,23 and p=0,008); anti-Scl70 (OR=0,29 and p=0,03); and Rodnan scores (OR=4,61; p=0,009) between patients with ACS with ILD and without ILD. There is a risk of decreased FVC in patients with positive anti Scl-70 antibodies (OR=0,37 and p=0,037). There is a correlation between FVC and Rodnan score (p=0,00).

Article Details

Keywords

Systemic scleroderma, interstitial lung injury,pulmonary hypertension

References

1. Gatta G, Di Grezia G, Iacomino A, et al. HRCT in systemic sclerosis: correlation between respiratory functional indexes and extension of lung failure. J Biol Regul Homeost Agents. 2013;27(2):579-587.
2. Lo Monaco A, Bruschi M, La Corte R, Volpinari S, Trotta F. Epidemiology of systemic sclerosis in a district of northern Italy. Clin Exp Rheumatol. 2011;29(2 Suppl 65):S10-14.
3. Trad S, Amoura Z, Beigelman C, et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum. 2006;54(1):184-191. doi:10.1002/ art.21538
4. Karassa FB, Ioannidis JPA. Mortality in systemic sclerosis. Clin Exp Rheumatol. 2008;26(5 Suppl 51):S85-93.
5. Walker UA, Tyndall A, Czirják L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis. 2007; 66(6): 754-763. doi:10.1136/ard.2006.062901
6. Peyman Mottaghi, Marzieh Daneshbodi, Mansoor Karimifar. Correlation between autoantibodies and internalorgans involvement in Iranian systemic sclerosispatients. Published online 2021.
7. Hikmat IH, Ramdhini SS, Soekersi H, Dewi S. Correlation between Interstitial Lung Disease Morphology Scores Based on High-resolution Computed Tomography Chest and Skin Fibrosis Degree Based on Modified Rodnan’s Skin Score on Systemic Sclerosis. Acta Medica Indones. 2021;53(3):254-260.
8. Matsuda KM, Yoshizaki A, Kuzumi A, et al. Skin thickness score as a surrogate marker of organ involvements in systemic sclerosis: a retrospective observational study. Arthritis Res Ther. 2019;21(1):129. doi:10.1186/s13075-019-1919-6